Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants

Abstract GSK3640254 (GSK'254) is a novel HIV‐1 maturation inhibitor with pharmacokinetics supporting once‐daily (QD) therapy for HIV‐1 treatment. This thorough QT/corrected QT (QTc) study evaluated the effect of GSK'254 on cardiac repolarization. In this two‐part, randomized study, healthy...

Full description

Bibliographic Details

Published in:	Pharmacology Research & Perspectives
Main Authors:	Ying Zhang, Mark Bush, Parto Yazdani, Joyce Zhan, Bo Wen, Veronica Bainbridge, Brian R. Wynne, Samit Joshi, Max Lataillade
Format:	Article
Language:	English
Published:	Wiley 2023-12-01
Subjects:	antiretrovirals drug safety phase I QT prolongation
Online Access:	https://doi.org/10.1002/prp2.1151